Factors and situations affecting the utility of patient preference studies: semi-structured interviews in Europe and the US
Frontiers in Pharmacology , Volume 10
Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical industry, regulatory authorities, and health technology assessment (HTA) bodies/payers for use in assessments and decision-making along the medical product lifecycle (MPLC). This study aimed to identify factors and situations that influence the value of patient preference studies (PPS) in decision-making along the MPLC according to different stakeholders. Methods: Semi-structured interviews (n = 143) were conducted with six different stakeholder groups (physicians, academics, industry representatives, regulators, HTA/ payer representatives, and a combined group of patients, caregivers, and patient representatives) from seven European countries (the United Kingdom, Sweden, Italy, Romania, Germany, France, and the Netherlands) and the United States. Framework analysis was performed using NVivo 11 software. Results: Fifteen factors affecting the value of PPS in the MPLC were identified. These are related to: study organization (expertise, financial resources, study duration, ethics and good practices, patient centeredness), study design (examining patient and/or other preferences, ensuring representativeness, matching method to research question, matching method to MPLC stage, validity and reliability, cognitive burden, patient education, attribute development), and study conduct (patients’ ability/willingness to participate and preference heterogeneity). Three types of situations affecting the use of PPS results were identified (stakeholder acceptance, market situations, and clinical situations). Conclusion: The factors and situation types affecting the value of PPS, as identified in this study, need to be considered when designing and conducting PPS in order to promote the integration of PPI into decision-making along the MPLC.
|patient preferences, drug life cycle, decision-making, health technology assessment, benefit risk assessment, market authorization|
|Frontiers in Pharmacology|
|Organisation||Institute for Medical Technology Assessment (iMTA)|
Whichello, C.L, van Overbeeke, E, Janssens, R, Scholin Bywall, K, Russo, S., Veldwijk, J, … de Bekker-Grob, E.W. (2019). Factors and situations affecting the utility of patient preference studies: semi-structured interviews in Europe and the US. Frontiers in Pharmacology, 10. Retrieved from http://hdl.handle.net/1765/127941